EBS
Price
$8.23
Change
-$0.16 (-1.91%)
Updated
Aug 29, 12:22 PM (EDT)
Capitalization
447.62M
68 days until earnings call
ZOMDF
Price
$0.04
Change
-$0.00 (-0.00%)
Updated
Aug 28 closing price
Capitalization
40.28M
Interact to see
Advertisement

EBS vs ZOMDF

Header iconEBS vs ZOMDF Comparison
Open Charts EBS vs ZOMDFBanner chart's image
Emergent Biosolutions
Price$8.23
Change-$0.16 (-1.91%)
Volume$100
Capitalization447.62M
Zomedica
Price$0.04
Change-$0.00 (-0.00%)
Volume$1.04M
Capitalization40.28M
EBS vs ZOMDF Comparison Chart in %
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. ZOMDF commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a StrongBuy and ZOMDF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (EBS: $8.39 vs. ZOMDF: $0.04)
Brand notoriety: EBS and ZOMDF are both not notable
EBS represents the Pharmaceuticals: Generic, while ZOMDF is part of the Medical/Nursing Services industry
Current volume relative to the 65-day Moving Average: EBS: 88% vs. ZOMDF: 92%
Market capitalization -- EBS: $447.62M vs. ZOMDF: $40.28M
EBS [@Pharmaceuticals: Generic] is valued at $447.62M. ZOMDF’s [@Medical/Nursing Services] market capitalization is $40.28M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The market cap for tickers in the [@Medical/Nursing Services] industry ranges from $228.64B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B. The average market capitalization across the [@Medical/Nursing Services] industry is $5.64B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 0 FA rating(s) are green whileZOMDF’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 0 green, 5 red.
  • ZOMDF’s FA Score: 1 green, 4 red.
According to our system of comparison, both EBS and ZOMDF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 5 TA indicator(s) are bullish while ZOMDF’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 5 bullish, 5 bearish.
  • ZOMDF’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ZOMDF is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Generic) experienced а -9.98% price change this week, while ZOMDF (@Medical/Nursing Services) price change was +0.24% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.17%. For the same industry, the average monthly price growth was +68.10%, and the average quarterly price growth was +81.88%.

The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.48%. For the same industry, the average monthly price growth was +6.46%, and the average quarterly price growth was +9.89%.

Reported Earning Dates

EBS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.17% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

@Medical/Nursing Services (+0.48% weekly)

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
EBS($448M) has a higher market cap than ZOMDF($40.3M). EBS YTD gains are higher at: -12.238 vs. ZOMDF (-65.750). EBS has higher annual earnings (EBITDA): 344M vs. ZOMDF (-36.65M). EBS has more cash in the bank: 267M vs. ZOMDF (58.1M). ZOMDF has less debt than EBS: ZOMDF (2.52M) vs EBS (668M). EBS has higher revenues than ZOMDF: EBS (812M) vs ZOMDF (28.4M).
EBSZOMDFEBS / ZOMDF
Capitalization448M40.3M1,112%
EBITDA344M-36.65M-939%
Gain YTD-12.238-65.75019%
P/E Ratio3.20N/A-
Revenue812M28.4M2,859%
Total Cash267M58.1M460%
Total Debt668M2.52M26,529%
FUNDAMENTALS RATINGS
EBS vs ZOMDF: Fundamental Ratings
EBS
ZOMDF
OUTLOOK RATING
1..100
185
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
29
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
4165
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
9085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZOMDF's Valuation (29) in the Pharmaceuticals Major industry is in the same range as EBS (53) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to EBS’s over the last 12 months.

ZOMDF's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as EBS (100) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to EBS’s over the last 12 months.

ZOMDF's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as EBS (100) in the Biotechnology industry. This means that ZOMDF’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (41) in the Biotechnology industry is in the same range as ZOMDF (65) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to ZOMDF’s over the last 12 months.

EBS's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ZOMDF (100) in the Pharmaceuticals Major industry. This means that EBS’s stock grew similarly to ZOMDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSZOMDF
RSI
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bearish Trend 2 days ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 2 days ago
81%
Declines
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ROIUF0.050.01
+34.43%
Route1 Inc.
AIBGY16.330.07
+0.40%
AIB Group PLC
NLLSY7.28N/A
N/A
Nel ASA
QNTQF6.50N/A
N/A
Qinetiq Group Plc.
NVYTF0.50N/A
N/A
Novacyt Clamart

ZOMDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZOMDF has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOMDF jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZOMDF
1D Price
Change %
ZOMDF100%
+0.24%
SNDL - ZOMDF
38%
Loosely correlated
+6.32%
CDNA - ZOMDF
30%
Poorly correlated
-1.35%
EBS - ZOMDF
29%
Poorly correlated
-2.33%
ARAY - ZOMDF
29%
Poorly correlated
-0.64%
BNR - ZOMDF
28%
Poorly correlated
-2.70%
More